Etelcalcetide
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Etelcalcetide: From Hyperparathyroidism to Hyperphosphatemia
One-Sentence Summary
Etelcalcetide is an intravenous calcimimetic, originally used to treat hyperparathyroidism (secondary hyperparathyroidism in dialysis patients). The TxGNN model predicts it may be effective for hyperphosphatemia, but there are currently no registered clinical trials and only 6 publications (1 RCT in the original indication, plus reviews, a preclinical study and case reports) in the data compiled for this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyperparathyroidism (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Hyperphosphatemia |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the compiled data. Based on known pharmacology, etelcalcetide is a calcimimetic that activates the calcium-sensing receptor (CaSR) and lowers parathyroid hormone (PTH). Its efficacy in secondary hyperparathyroidism of chronic kidney disease is established, and mechanistically it may be applicable to hyperphosphatemia.
Hyperphosphatemia and secondary hyperparathyroidism are closely linked in dialysis patients. Phosphate retention drives PTH secretion, and lowering PTH can indirectly improve mineral metabolism (calcium, phosphate, FGF23). The effect is therefore likely indirect and secondary to PTH suppression, not a direct phosphate-lowering action.
A 2026 preclinical report (PMID 42044867) suggests that etelcalcetide may restore cardiac function in chronic hyperphosphatemia through CaSR-cAMP activation. This adds biological plausibility but is not clinical evidence of phosphate control.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33305109 | 2020 | RCT | Kidney Int Rep | DUET trial: prospective randomized trial of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism (original indication) |
| 29440923 | 2018 | Review | Int J Nephrol Renovasc Dis | Role of etelcalcetide in managing hyperparathyroidism in hemodialysis; reduces PTH when given thrice weekly after dialysis |
| 42495460 | 2026 | Review | Cureus | Narrative review of calcimimetics, vitamin D analogs and phosphate binders for secondary hyperparathyroidism in dialysis |
| 42044867 | 2026 | Preclinical | Kidney Int | Etelcalcetide restores cardiac function in chronic hyperphosphatemia via CaSR-cAMP activation |
| 42853437 | 2026 | Case report | CEN Case Rep | Regression of uremic tumoral calcinosis after switching from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia |
| 33211001 | 2021 | Case report | Clin Nephrol | Temporary metastatic pulmonary calcification in a peritoneal dialysis patient with hyperparathyroidism |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15450P | PARSABIV Solution for Injection 2.5 mg/0.5 mL | Injection, solution | Not recorded |
| SIN15452P | PARSABIV Solution for Injection 10 mg/2 mL | Injection, solution | Not recorded |
| SIN15451P | PARSABIV Solution for Injection 5 mg/mL | Injection, solution | Not recorded |
Safety Considerations
- Drug Interactions: 21 interactions were found, mostly rated Major. Main ones include:
- Other calcimimetics: cinacalcet
- Bisphosphonates: alendronic acid, risedronic acid, ibandronate, pamidronic acid, zoledronic acid, etidronic acid, tiludronic acid
- Other bone and calcium-lowering agents: denosumab, romosozumab, salmon calcitonin
- Loop diuretics: furosemide, bumetanide, torasemide, etacrynic acid
- Others: amifostine, pentamidine, cisplatin, foscarnet (Major); burosumab (Moderate)
Many of these combinations may add to calcium-lowering effects, so hypocalcemia is the likely concern.
For other safety information (warnings and contraindications), please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a plausible but indirect mechanism, since any phosphate benefit would come from PTH suppression. There are no registered trials, and the only RCT addresses the original indication, not hyperphosphatemia. Package insert safety data has also not been reviewed, which blocks safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, to complete safety screening
- Detailed mechanism of action data (MOA)
- Evidence that etelcalcetide lowers serum phosphate or improves clinical outcomes in hyperphosphatemia, for example from the existing SHPT trial data or a new study
- A hypocalcemia monitoring plan, given the many interacting calcium-lowering drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.